WSJ ArticleNew article lumping Concordia in with Valeant, Horizon Pharma and Mallinckrodt.
https://www.wsj.com/articles/concerns-over-valeant-spread-to-other-drug-makers-1448240861
Looks like either poor research into Concordia or outright distortion. Here are some highlights:
"Concordia didn’t respond to requests for comment, but has said its drug prices are competitive with other products on the market."
"Concordia Healthcare is among the most aggressive newcomers to build its business through acquiring older or off-patent drugs and raising their prices significantly, says Jessica Gladstone, an analyst at Moody’s Investors Service."
I find this 2nd quote very curious, as Concordia has been relatively aggressive in the acquisitions, but certainly can not be considered to be even close to the most aggressive in price increases. I am looking through all of the available articles of Jessica Gladstone on Moody's but cannot find a similar quote. I have emailed the author directly asking for clarification on the source of this.
GL all.